Salinomycin: A new paradigm in cancer therapy

Intratumoral immunization: a new paradigm for cancer therapy.

Immune cell infiltration in the tumor microenvironment is of prognostic and therapeutic import. These immune cell subsets can be heterogeneous and are composed of mature antigen-presenting cells, helper and effector cytotoxic T cells, toleragenic dendritic cells, tumor-associated macrophages, and regulatory T cells, among other cell types. With the development of novel drugs that target the imm...

A new paradigm shift in antithrombotic therapy

Decades after the introduction of oral anti-coagulants namely the vitamin K antagonist (VKA) Warfarin and antiplatelet agents such as Aspirin and Plavix, new classes of direct, small molecule, novel oral anti-coagulant medications and antiplatelet P2Y12 receptor inhibitors have recently become available. For the novel oral anticoagulants (NOAC), these agents can be separated by direct thrombin ...

Ozone Therapy: A New Paradigm in Periodontics

The oral cavity appears as an open ecosystem, with a dynamic balance between the entrances of microorganisms, colonization modalities, and host defenses aimed to their removal. Gingival and Periodontal diseases represent a major concern both in dentistry and medicine. The oral biofilm formation and development, and the inside selection of specific microorganisms have been correlated with the mo...

Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?

Cytotoxic chemotherapy in the treatment of tumors has traditionally been thought to be immunosuppressive. Increasing evidence suggests the contrary and has introduced the concept of 'immunogenic' chemotherapy or, in other words, the concept that the innate and adaptive immune systems are critical in determining the long-term efficacy of some cytotoxic-based (and radiotherapy-based) regimens. Th...

Low level laser therapy (LLLT): a new paradigm in the management of cancer therapy-induced mucositis ?